From promise to performance : a journey of transformation at SmithKline Beecham / by Bauman, Robert P. (Robert Patten), 1931-, Jackson, Peter, 1943-, Lawrence, Joanne T.

Subjects: “…SmithKline Beecham Pharmaceuticals…”

Investing in Biotechnology Stocks / by Gough, Leo, author 315573

“…Leading investment author and journalist Leo Gough provides them with a rare insider's look at the biotech industries based on extensive interviews with industry analysts, CEOs, and leading scientists at top biotech firms, including Merck & Co., Eli Lilly & Co., Amgen Ltd., SmithKline Beecham, Inc., Genzyme Corp., Monsanto, and others.…”

Imunogenitas dan Keamanan Vaksin Varisela pada Anak Sehat by Hindra Irawan Satari, Sri Rezeki Hadinegoro, Alan R Tumbelaka, Hardjono Abdoerrachman, Htay H Han, Bock H

Get full text

Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia by Kamgno J., Boussinesq M.

“…A trial was performed in Central Cameroon, whose aim was to follow up for 1 0 months, and to compare the changes in the Loa microfilarial loads in two groups of patients, one treated with a single dose (600 mg) of albendazole (Alben®, SmithKline Beecham) given with fatty food, and the other treated with mebendazole (100 mg, twice a day, generic tablets) at a fasting state. …”
Get full text

A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. by English, M, MacLennan, J, Bowen-Morris, J, Deeks, J, Boardman, M, Brown, K, Smith, S, Buttery, J, Clarke, J, Quataert, S, Lockhart, S, Moxon, E

“…Control children received three doses of Hepatitis B vaccine (Engerix B(R); SmithKline Beecham). At 5 months of age, 100% of children receiving the conjugate vaccine had specific immunoglobulin G concentrations >2.0 microg/ml (n=116) compared with only 4% of control children (n=121). …”

Scientific Opinion on the substantiation of a health claim related to caffeine and increased alertness pursuant to Article 13(5) of Regulation (EC) No 1924/2006 by EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

“…Following an application from SmithKline Beecham Limited, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of United Kingdom, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to caffeine and increased alertness. …”
Get full text